| Identification | Back Directory | [Name]
Tariquidar | [CAS]
206873-63-4 | [Synonyms]
Xr9576
CS-678
XL9576
D06008
Xr 9576
Tariquidar
Unii-J58862dtvd
XL9576 Free base
Tariquidar, >=98%
Tariquidar(XR9576)
Tariquidar USP/EP/BP
XR 9576;XR-9576;D06008
N-(2-((4-(2-(6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)ethyl)phenyl)carbamoyl)-4,5-dimethoxyphenyl)quinoline-3-carboxamide
N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxy-phenyl]quinoline-3-carboxamide
N-[2-({4-[2-(6,7-diMethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl}carbaMoyl)-4,5-diMethoxyphenyl]quinoline-3-carboxaMide
N-[2-[N-[4-[2-(6,7-DiMethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)ethyl]phenyl]carbaMoyl]-4,5-diMethoxyphenyl]quinoline-3-carboxaMide
N-[2-[[[4-[2-(3,4-Dihydro-6,7-diMethoxy-isoquinolin-2(1H)-yl)ethyl]phenyl]aMino]carbonyl]-4,5-diMethoxyphenyl]-3-quinolinecarboxaMide
3-Quinolinecarboxamide, N-(2-(((4-(2-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)ethyl)phenyl)amino)carbonyl)-4,5-dimethoxyphenyl)-
N-[2-[[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide Tariquidar
Tariquidar
N-[2-[[4-[2-(6,7-Dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide | [Molecular Formula]
C38H38N4O6 | [MDL Number]
MFCD09837824 | [MOL File]
206873-63-4.mol | [Molecular Weight]
646.73 |
| Chemical Properties | Back Directory | [Melting point ]
>190oC (dec.) | [Boiling point ]
716.0±60.0 °C(Predicted) | [density ]
1.276±0.06 g/cm3(Predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO (Slightly), Methanol (Slightly) | [form ]
powder | [pka]
10.67±0.70(Predicted) | [color ]
white to light brown | [InChIKey]
LGGHDPFKSSRQNS-UHFFFAOYSA-N | [SMILES]
N1C2C(=CC=CC=2)C=C(C(NC2=CC(OC)=C(OC)C=C2C(NC2=CC=C(CCN3CCC4=C(C3)C=C(OC)C(OC)=C4)C=C2)=O)=O)C=1 |
| Hazard Information | Back Directory | [Description]
Tariquidar is an anthranilic acid derivative that binds to P-glycoprotein (Kd = 5.1 nM) and inhibits transport activity.1 It inhibits transport of vinblastine (Item No. 11762) and paclitaxel (Item No. 10461) in multidrug resistant CHrB30 cells, increasing the steady state accumulation to non-P-glycoprotein-expressing multidrug sensitive cell levels (EC50 = 487 nM). Tariquidar also enhances the distribution of its substrates, increasing the amount of substrate entering the CNS.2 When administered at doses of 2 and 6.25 mg/kg in mice in combination with the peripherally-restricted opioid loperamide, the latency to paw withdrawal in a hot plate assay increases, indicating that loperamide is transported into the CNS. | [Uses]
Tariquidar is a p-glycoprotein drug efflux pump inhibitor. Tariquidar inhibits the ATPase activity of P-glycoprotein, suggesting that the modulating effect is derived from the inhibition of substrate
binding, inhibition of ATP hydrolysis or both.Tariquidar can be considered an ideal agent for testing the role of P-glycoprotein inhibition in cancer | [Definition]
ChEBI: Tariquidar is a member of benzamides. | [Biochem/physiol Actions]
Specific inhibitor of MDR-1 (P-gp) | [target]
P-glycoprotein | [References]
[1] CATHERINE MARTIN. The molecular interaction of the high affinity reversal agent XR9576 with P-glycoprotein[J]. British Journal of Pharmacology, 2009, 128 2: 403-411. DOI: 10.1038/sj.bjp.0702807
[2] EDNA F CHOO. Differential in vivo sensitivity to inhibition of P-glycoprotein located in lymphocytes, testes, and the blood-brain barrier.[J]. Journal of Pharmacology and Experimental Therapeutics, 2006, 317 3: 1012-1018. DOI: 10.1124/jpet.105.099648 |
|
|